UV Flu Technologies to Commence a National TV Advertising Campaign
CENTERVILLE, Mass., May 16, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a television joint venture agreement with Stardust International TV, of San Bernardino Ca., for the filming of a 60 second commercial, along with a 10 minute, "mini-infomercial." The commercial will run locally, regionally, and nationally, on a variety of television networks, including Comcast and Direct TV. The commercials will be run several hundred times to a potential audience of over 40 million households, while the mini-infomercial will run 4 times weekly to a variety of television stations.
"We think this is an outstanding opportunity to create brand awareness and sales for UV Flu," said Jack Lennon, President of UV Flu Technology. "Our FDA cleared device utilizes patented break thru technology that eliminates the issues of maintenance and efficacy present in almost all but the most costly filter systems. The Viratech UV-400 patented technology kills airborne bacteria, reduces odors, volatile organic compounds, and a host of other airborne contaminants. Indoor Air Pollution has been shown to have direct links to sleep disorders, respiratory issues including asthma and allergies, cancer, diabetes and even the risk of stroke."
"Finally having a national TV commercial, that can educate the American consumer about the health benefits of using our device and breathing contaminant-free air indoors, we think will dramatically improve the awareness of our brand, and the importance of the whole space as well," said Mr. Lennon. "The recently announced launch of the Serta Ultimate Sleep System, which combines our Viratech air purifier, with one of Serta's finest memory foam mattresses, coupled with their local advertising and our new 60 second national commercial, should have a significant impact on long-term sales."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the worlds' finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
SOURCE UV Flu Technologies, Inc.